Evidence map›Paper›PMID 39772635›Full record

ArticleNano letters2025

Regulation of Cell-Nanoparticle Interactions through Mechanobiology.

Marco Cassani, Francesco Niro, Soraia Fernandes, Daniel Pereira-Sousa, Sofia Faes Morazzo, Helena Durikova, Tianzheng Wang, Lara González-Cabaleiro, Jan Vrbsky, Jorge Oliver-De La Cruz and 6 more

Abstract read
In one paragraph

Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Marco CassaniInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.ORCID 0000-0001-8437-7734
Francesco NiroInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
Soraia FernandesInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
Daniel Pereira-SousaInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
Sofia Faes MorazzoInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.ORCID 0000-0001-6864-5209
Helena DurikovaInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.ORCID 0000-0001-6613-9177
Tianzheng WangDepartment of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.
Lara González-CabaleiroDepartamento de Química Física, Universidade de Vigo, Campus Universitario As Lagoas Marcosende, Vigo 36310, Spain.
Jan VrbskyInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
Jorge Oliver-De La CruzInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.
Simon KlimovicNanobiotechnology Core Facility, CEITEC Masaryk University, 62500 Brno, Czech Republic.
Jan PribylNanobiotechnology Core Facility, CEITEC Masaryk University, 62500 Brno, Czech Republic.ORCID 0000-0003-1232-3694
Tomas LojaMolecular Medicine, CEITEC Masaryk University, 62500 Brno, Czech Republic.
Petr SkladalDepartment of Biochemistry, Faculty of Science, Masaryk University, 62500 Brno, Czech Republic.
Frank CarusoDepartment of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0002-0197-497X
Giancarlo ForteInternational Clinical Research Center, St. Anne's University Hospital, 65691 Brno, Czech Republic.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bio-nano interactions have been extensively explored in nanomedicine to develop selective delivery strategies and reduce systemic toxicity. To enhance the delivery of nanocarriers to cancer cells and improve the therapeutic efficiency, different nanomaterials have been developed. However, the limited clinical translation of nanoparticle-based therapies, largely due to issues associated with poor targeting, requires a deeper understanding of the biological phenomena underlying cell-nanoparticle interactions. In this context, we investigate the molecular and cellular mechanobiology parameters that control such interactions. We demonstrate that the pharmacological inhibition or the genetic ablation of the key mechanosensitive component of the Hippo pathway, i.e., yes-associated protein, enhances nanoparticle internalization by 1.5-fold. Importantly, this phenomenon occurs independently of nanoparticle properties, such as size, or cell properties such as surface area and stiffness. Our study reveals that the internalization of nanoparticles in target cells can be controlled by modulating cell mechanosensing pathways, potentially enhancing nanotherapy specificity.

Indexed as

Adaptor Proteins, Signal TransducingNanoparticlesHippo Signaling PathwayHumansMechanotransduction, CellularNanomedicineProtein Serine-Threonine KinasesYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingProtein Serine-Threonine KinasesYAP1 protein, humanYAP-Signaling Proteinsbio−nano interactionsmechanobiologymechanotransductionnanoparticles

Identifiers

PMID39772635
PMCPMC11849000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.